BCAL DiagnosticsASX:BDX -3.70% Altman Z-Score is -1.19 as of Jun. 28, 2026. The stock has 3 warning signs investors should review. Among 201 Medical Diagnostics & Research companies, BCAL Diagnostics ranks worse than 78.11% on this metric.
The Altman Z-Score is a model designed to predict the likelihood of a company going bankrupt within the next two years. Created by American finance professor Edward Altman in 1968, the model is specifically designed for publicly traded manufacturing companies with assets greater than $1 million.
Warning Sign:
Altman Z-score of -1.19 is in distress zone. This implies bankruptcy possibility in the next two years.
BCAL Diagnostics has a Altman Z-Score of -1.19, indicating it is in Distress Zones. This implies bankrupcy possibility in the next two years.
The zones of discrimination were as such:
When Altman Z-Score <= 1.8, it is in Distress Zones.
When Altman Z-Score >= 3, it is in Safe Zones.
When Altman Z-Score is between 1.8 and 3, it is in Grey Zones.
The historical rank and industry rank for BCAL Diagnostics's Altman Z-Score or its related term are showing as below:
ASX:BDX'
s Altman Z-Score Range Over the Past 10 Years
Min: -2.12 Med: -2.12 Max: -1.19
Current: -1.19
During the past 4 years, BCAL Diagnostics's highest Altman Z-Score was -1.19. The lowest was -2.12. And the median was -2.12.
X1: The Working Capital/Total Assets (WC/TA) ratio is a measure of the net liquid assets of the firm relative to the total capitalization. Working capital is defined as the difference between current assets and current liabilities. Ordinarily, a firm experiencing consistent operating losses will have shrinking current assets in relation to total assets. Altman found this one proved to be the most valuable liquidity ratio comparing with the current ratio and the quick ratio. This is however the least significant of the five factors.
X2: Retained Earnings/Total Assets: the RE/TA ratio measures the leverage of a firm. Retained earnings is the account which reports the total amount of reinvested earnings and/or losses of a firm over its entire life. Those firms with high RE, relative to TA, have financed their assets through retention of profits and have not utilized as much debt.
X3, Earnings Before Interest and Taxes/Total Assets (EBIT/TA): This ratio is a measure of the true productivity of the firm's assets, independent of any tax or leverage factors. Since a firm's ultimate existence is based on the earning power of its assets, this ratio appears to be particularly appropriate for studies dealing with corporate failure. This ratio continually outperforms other profitability measures, including cash flow.
X4, Market Value of Equity/Book Value of Total Liabilities (MVE/TL): The measure shows how much the firm's assets can decline in value (measured by market value of equity plus debt) before the liabilities exceed the assets and the firm becomes insolvent.
X5, Revenue/Total Assets (S/TA): The capital-turnover ratio is a standard financial ratio illustrating the sales generating ability of the firm's assets.
Altman Z-Score does not apply to financial companies.
BCAL Diagnostics Altman Z-Score Related Terms
BCAL Diagnostics Altman Z-Score Historical Data
* Premium members only.
The historical data trend for BCAL Diagnostics's Altman Z-Score can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:BDX vs TMO, DHR, IDXX: Altman Z-Score Comparison
For the Diagnostics & Research subindustry, BCAL Diagnostics's Altman Z-Score, along with its competitors' market caps and Altman Z-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BCAL Diagnostics Altman Z-Score vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, BCAL Diagnostics's Altman Z-Score distribution charts can be found below:
* The bar in red indicates where BCAL Diagnostics's Altman Z-Score falls into.
Altman Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.
BCAL Diagnostics's Altman Z-Score for today is calculated with this formula:
Z
=
1.2
*
X1
+
1.4
*
X2
+
3.3
*
X3
+
0.6
*
X4
+
1.0
*
X5
=
1.2
*
0.4125
+
1.4
*
-2.8339
+
3.3
*
-0.7261
+
0.6
*
7.7975
+
1.0
*
0.0022
=
-1.19
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency. GuruFocus does not calculate Altman Z-Score when X4 or X5 value is 0.
BCAL Diagnostics (ASX:BDX) has a Altman Z-Score of -1.19 as of Jun. 28, 2026. The Altman Z-score measures a company's bankruptcy risk. View historical data on BCAL Diagnostics and its competitors. According to the industry distribution chart, BCAL Diagnostics ranks #157 out of 201 companies in the Medical Diagnostics & Research industry, placing it in the top 78.1%.
Is BCAL Diagnostics' Altman Z-Score too high?
BCAL Diagnostics' current Altman Z-Score is -1.19. Based on the distribution chart, BCAL Diagnostics ranks #157 out of 201 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers.
How does BCAL Diagnostics' Altman Z-Score compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, BCAL Diagnostics ranks #157 out of 201 companies for Altman Z-Score. This places BCAL Diagnostics in the lower half of its industry. The industry median Altman Z-Score is 2.40. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Altman Z-Score for a Medical Diagnostics & Research company?
The median Altman Z-Score among Medical Diagnostics & Research companies is 2.40, based on 201 companies in the industry. Companies in the top quartile (top 25%) have a Altman Z-Score significantly above this median, while those in the bottom quartile fall well below. However, Altman Z-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Altman Z-Score mean?
A high Altman Z-Score can signal that a stock is expensive relative to its fundamentals. The Altman Z-score measures a company's bankruptcy risk. View historical data on BCAL Diagnostics and its competitors. For the Medical Diagnostics & Research industry, the median Altman Z-Score is 2.40 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BCAL Diagnostics's current Altman Z-Score is -1.19. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BCAL Diagnostics stock overvalued right now?
BCAL Diagnostics (ASX:BDX) has a current Altman Z-Score of -1.19. The current Altman Z-Score is -1.19. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Altman Z-Score calculated?
Altman Z-Score is calculated from a company's financial statements. For BCAL Diagnostics (ASX:BDX), the current Altman Z-Score is -1.19 as of Jun. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
BCAL Diagnostics Ltd is a biotechnology company developing a novel blood screening test to improve the early diagnosis and monitoring of breast cancer that is safe, cost-effective, accurate, and available to all women regardless of age, race, and geographic location.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:BDX has been successfully added to your 